Royalty Pharma plc
$25.25
Stock Quotes & Analysis
RPRX
1.32%
$25.25
Latest AAPL News (Need to figure out how to make this dynamic)
Graphene is an excellent conductor of electricity and heat, surpassing traditional materials like silicon, and…
The ballots have been counted, the speeches have been made, and the confetti has settled.…
The political winds are shifting, and Wall Street is taking notice. As Donald Trump’s approval…
In the shadows of Silicon Valley’s AI frenzy, a sleeping giant is awakening. While tech…
Royalty Pharma plc
Status: Active
Sector: Healthcare
Industry: Biotechnology
Symbol: RPRX
Exchange: NMS
Employees:
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street, New York, NY, United States | |
212 883 0200 | |
https://www.royaltypharma.com |